Siem obtained his PhD in medical pharmacology in 2008 at the University of Leiden, the Netherlands. Entrepreneurial scientist, he contributed to over 20 publications and 5 patents. His career has been in science management in top-end research facilities in Australia, the Netherlands and France. He has conducted research and managed teams in both public research institutes and biotechnology company.
Khaled obtained his PhD in biology in 2010 at the University Pierre and Marie Curie, Paris, France. After a post-doctorate in biology and biochemistry at the Centre of Research in Cell Biology of Montpellier, he completed a master in business administration at the University School of Management of Montpellier (IAE). He was previously marketing innovation analyst at Horiba Medical, a world leader of in vitro diagnostics, where he defined commercial value of new medical innovations, and liaised with KOLs to understand unmet needs in clinical care.
Krzysztof obtained his PhD in cellular biology in 2005 from University of Georgia, Athens, USA. He is now team leader of the research group ‘Tubulin Code’ at the Institute of Human Genetics (IGH) in Montpellier and supports MT-act as member of the Scientific Advisory Board (SAB). He dedicated his scientific career unravelling the biology of microtubules. He is an internationally renowned scientist in the field as his work yielded outstanding breakthrough discoveries that led to the identification of over 20 microtubule-modifying enzymes. His work has been published in top-end scientific journals including Science, Cell, Molecular Cell and Developmental Cell.
Guillaume is a seasoned protein biochemist trained to microtubule biochemistry in the ‘Tubulin code’ team at the Institute of Human Genetics (IGH) in Montpellier. He masters microtubule (MT) related biochemistry and further developed skills in bio-informatics applied to drug design. Guillaume has over 10 years applied biochemistry expertise and worked in governmental research organizations, SMEs and large companies.